Inactive Instrument

Other languages Sunshine Biopharma, Inc. Other OTC

Equities

US8677811064

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sunshine Biopharma Shares Slump After Reverse Stock Split Announcement	Apr. 12
Sunshine Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Sunshine Biopharma, Inc. Announces Executive Changes	Jan. 30
Sunshine Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Jewish General Hospital Announces Termination of the Research Agreement with Sunshine Biopharma, Inc	Nov. 02
Sunshine Biopharma Gets Extension to Comply With Nasdaq Minimum Bid Price Rule	23-09-22
Sunshine Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Wall Street Set to Open Higher; Import Prices Rebound More Than Expected	23-05-12
Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Sunshine Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-04
Sunshine Biopharma, Inc. Signs Exclusive Worldwide License with University of Arizona for PLpro-Based Covid-19 Treatment	23-02-28
Sector Update: Health Care Stocks Rise on Friday	23-02-10
Sunshine Biopharma Signs Research Deal with Canadian Hospital for Anticancer Compound; Shares Rise	23-02-10
Sunshine Biopharma Signs Research Agreement with the Jewish General Hospital to Advance the Development of Adva-27A Anticancer Compound	23-02-10
Sunshine Biopharma Signs Research Agreement with the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound	23-02-10
Sunshine Biopharma Launches $2 Million Share Buyback Program; Shares Down Pre-Bell	23-01-19
Sunshine Biopharma, Inc. announces an Equity Buyback for $2 million worth of its shares.	23-01-19
Sunshine Biopharma, Inc. authorizes a Buyback Plan.	23-01-18
Sunshine Biopharma Collaborates With Unnamed Lipid Nanoparticle Company to Develop Anticancer Macromolecule K1.1	22-11-16
Sunshine Biopharma Enters into Collaboration Agreement with Lipid Nanoparticle Formulation Company for K1.1 Anticancer mRNA Project	22-11-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sunshine Biopharma, Inc. Other OTC

Equities

US8677811064

Other languages

Filters